<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485184</url>
  </required_header>
  <id_info>
    <org_study_id>PVT-TIPS2</org_study_id>
    <nct_id>NCT02485184</nct_id>
  </id_info>
  <brief_title>TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis</brief_title>
  <official_title>TIPS Versus Endoscopic Therapy for the Prevention of Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Occlusive portal vein thrombosis may be a negative prognostic marker of variceal bleeding in
      liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy,
      transjugular intrahepatic portosystemic shunt may further improve the outcomes of occlusive
      portal vein thrombosis in liver cirrhosis with variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Occlusive portal vein thrombosis may be a negative prognostic marker of variceal bleeding in
      liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy,
      transjugular intrahepatic portosystemic shunt may further improve the outcomes of occlusive
      portal vein thrombosis in liver cirrhosis with variceal bleeding. However, the safety of
      transjugular intrahepatic portosystemic shunt remains uncertain in patients with occlusive
      portal vein thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variceal rebleeding</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative rates free of variceal rebleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Portal vein recanalization</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of portal vein recanalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related complications</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of treatment-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transjugular intrahepatic portosystemic shunt success rate</measure>
    <time_frame>3 years</time_frame>
    <description>Technical success rate of transjugular intrahepatic portosystemic shunt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal bleeding-related mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Variceal bleeding-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>TIPS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transjugular intrahepatic portosystemic shunt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic therapy.
Non-selective beta blockers.
Anticoagulation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transjugular intrahepatic portosystemic shunt</intervention_name>
    <description>Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.</description>
    <arm_group_label>TIPS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-selective beta blockers</intervention_name>
    <description>Non-selective beta blockers are the drugs for reducing the portal pressure.</description>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
    <other_name>propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic therapy</intervention_name>
    <description>Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.</description>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation</intervention_name>
    <description>Anticoagulation therapy includes heparin and warfarin.</description>
    <arm_group_label>ET &amp; drugs groups</arm_group_label>
    <other_name>warfarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Liver cirrhosis.

          2. History of variceal bleeding.

          3. Occlusive portal vein thrombosis on axial contrast-enhanced CT scans

          4. Age 18-65 years.

          5. Written informed consents.

          6. Adequate liver and renal function.

        Exclusion Criteria:

          1. Active bleeding.

          2. Recent variceal bleeding more than 3 months before our admission.

          3. Partial portal vein thrombosis.

          4. Fibrotic cord of main portal vein.

          5. Complete superior mesenteric vein thrombosis.

          6. Not eligible for transjugular intrahepatic portosystemic shunt.

          7. Not eligible for anticoagulation therapy.

          8. Not eligible for non-selective beta blockers.

          9. Severe heart and lung diseases.

        9. Uncontrolled infection and sepsis. 10. Malignancy. 11. Previous shunt surgery. 12.
        Pregnancy and breastfeeding. 13. HIV infection. 14. Oral administration. 15. Poor
        adherence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guohong Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital of Digestive Diseases, Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingshun Qi, MD</last_name>
    <email>xingshunqi@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guohong Han, MD</last_name>
    <email>guohhan@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Han G, Qi X, He C, Yin Z, Wang J, Xia J, Yang Z, Bai M, Meng X, Niu J, Wu K, Fan D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011 Jan;54(1):78-88. doi: 10.1016/j.jhep.2010.06.029. Epub 2010 Aug 27.</citation>
    <PMID>20932597</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>June 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Guohong Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
